MNKDMANNKIND CORP同业对比
MANNKIND CORP 与Pharmaceutical Preparations的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Pharmaceutical Preparations)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MNKD本股 | $1.1B#8 | — | — | 3.3x#4 | 22.2%#3 | -78.7%#11 | 11.1%#3 | — | 2283.8%#1 | — | -33.8%#12 | — |
| HROW | $1.3B#1 | — | 84.4x#12 | 4.7x#5 | 36.4%#1 | 70.6%#3 | 11.2%#2 | -33.8%#8 | 13.2%#3 | 6#1 | -20.2%#10 | — |
| RARE | $1.3B#2 | — | — | 1.9x#2 | 20.2%#4 | -1.1%#4 | -79.5%#5 | — | — | — | -56.3%#13 | — |
| OMER | $1.3B#3 | 10.0x#1 | — | 17.0x#7 | -34.0%#8 | 97.9%#1 | -166.4%#6 | — | -151.8%#6 | — | 328.7%#3 | — |
| AKTS | $1.2B#4 | — | 2.5x#6 | — | — | — | — | 0.0%#2 | — | — | 23319.4%#1 | — |
| OPK | $1.2B#5 | — | 1.0x#1 | 2.0x#3 | -14.9%#7 | -324.0%#14 | -19.3%#4 | -19058.1%#12 | -13.3%#4 | 4#3 | 16.2%#8 | — |
| SPTX | $1.2B#6 | — | 2.8x#7 | — | — | — | — | 0.0%#2 | — | — | — | — |
| ANRO | $1.2B#7 | — | 5.4x#9 | — | — | -2.9%#5 | — | -28.8%#6 | — | — | 664.8%#2 | — |
| MLTX | $1.1B#9 | — | 2.5x#5 | — | — | -91.1%#13 | — | -53.1%#9 | -491.6%#7 | — | -76.6%#14 | — |
| JBIO | $1.1B#10 | — | 2.4x#4 | — | — | -83.0%#12 | — | -29.0%#7 | — | — | 133.9%#4 | — |
| SVRA | $1.1B#11 | — | 7.4x#10 | 4109.2x#9 | — | -23.9%#7 | -48072.8%#9 | -82.7%#10 | -93.6%#5 | — | 41.8%#6 | — |
| OBX | $1.1B#12 | — | — | — | — | -21.1%#6 | — | — | — | — | — | — |
| CRVS | $1.0B#13 | — | 4.6x#8 | — | — | 75.4%#2 | — | -6.8%#4 | — | — | 112.5%#5 | — |
| AMPH | $1.0B#14 | 14.2x#2 | 2.3x#3 | 1.4x#1 | -1.7%#5 | -38.5%#8 | 19.5%#1 | 22.0%#1 | 13.2%#2 | 5#2 | -11.1%#9 | — |
| KURA | $996M#15 | — | 20.6x#11 | 14.8x#6 | 25.2%#2 | -60.2%#9 | -449.9%#7 | -575.4%#11 | — | — | 34.0%#7 | — |
| JANX | $993M#16 | — | 1.1x#2 | 99.3x#8 | -5.6%#6 | -64.7%#10 | -1576.7%#8 | -12.2%#5 | — | — | -30.6%#11 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议